ENTRY       D11530                      Drug
NAME        Sutimlimab (USAN/INN);
            Sutimlimab (genetical recombination) (JAN);
            Sutimlimab-jome;
            Enjaymo (TN)
PRODUCT     ENJAYMO (Bioverativ Therapeutics)
FORMULA     C6436H9912N1700O2016S46
EXACT_MASS  144743.2507
MOL_WEIGHT  144832.7369
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVKPGGSLRL SCAASGFTFS NYAMSWVRQA PGKGLEWVAT ISSGGSHTYY
            LDSVKGRFTI SRDNSKNTLY LQMNSLRAED TALYYCARLF TGYAMDYWGQ GTLVTVSSAS
            TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTKTYT CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFEGGPSVFL
            FPPKPKDTLM ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV
            VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP PSQEEMTKNQ
            VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSRLTV DKSRWQEGNV
            FSCSVMHEAL HNHYTQKSLS LSLGK
            (Light chain)
            QIVLTQSPAT LSLSPGERAT MSCTASSSVS SSYLHWYQQK PGKAPKLWIY STSNLASGVP
            SRFSGSGSGT DYTLTISSLQ PEDFATYYCH QYYRLPPITF GQGTKLEIKR TVAAPSVFIF
            PPSDEQLKSG TASVVCLLNN FYPREAKVQW KVDNALQSGN SQESVTEQDS KDSTYSLSST
            LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGEC
            (Disulfide bridge: H22-H96, H132-L216, H145-H201, H224-H'224, H227-H'227, H259-H319, H365-H423, H'22-H'96, H'132-L'216, H'145-H'201, H'259-H'319, H'365-H'423, L23-L89, L136-L196, L'23-L'89, L'136-L'196)
  TYPE      Peptide
REMARK      Therapeutic category: 6399
            ATC code: L04AA55
            Product: D11530<JP/US>
EFFICACY    Anti-anemic, Anti-complement C1s antibody
  DISEASE   Cold agglutinin disease [DS:H01585]
  TYPE      Monoclonal antibody
TARGET      C1S [HSA:716] [KO:K01331]
  PATHWAY   hsa04610(716)  Complement and coagulation cascades
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA55 Sutimlimab
                  D11530  Sutimlimab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Complement Inhibitors
                Sutimlimab
                 D11530  Sutimlimab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              63  Biological preparations
               639  Miscellaneous
                6399  Others
                 D11530  Sutimlimab (USAN/INN); Sutimlimab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                C1S
                 D11530  Sutimlimab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11530
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11530
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11530
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11530
DBLINKS     CAS: 2049079-64-1
            PubChem: 384585506
///
